Table 2.
Variable | Runoff Characteristics | p Value | |
---|---|---|---|
Normal (n = 100) | Slow (n = 24) | ||
Age (years) | 50.53 ± 12.35 | 47.70 ± 13.28 | =0.3 |
Male-# pts (%) | 67 (67%) | 15 (62.5%) | =0.7 |
BMI | 27.70 ± 5.20 | 27.79 ± 6.87 | =0.7 |
Hypertension-# pts (%) | 71 (71%) | 17 (70.8%) | =1.0 |
Diabetes mellitus-# pts (%) | 15 (15%) | 2 (8.3%) | =0.4 |
Glycemia (mg/dL) | 104.89 ± 27.33 | 110.48 ± 48.55 | =0.4 |
Total cholesterol (mg/dL) | 167.26 ± 43.49 | 182.96 ± 40.27 | =0.1 |
HDL (mg/dL) | 50.24 ± 16.86 | 46.65 ± 9.31 | =0.3 |
LDL (mg/dL) | 94.56 ± 35.35 | 113.28 ± 43.24 | =0.03 |
Triglycerides (mg/dL) | 115.53 ± 62.81 | 133.57 ± 86.55 | =0.2 |
Smoking-# pts (%) | 15 (15%) | 6 (25%) | =0.2 |
Angina-# pts (%) | 32 (32%) | 12 (50%) | =0.4 |
NYHA II-# pts (%) | 21 (65.6%) | 6 (85.7%) | - |
NYHA III-# pts (%) | 10 (31.3%) | 1 (14.3%) | - |
NYHA IV-# pts (%) | 1 (3.1%) | 0 (0%) | =0.1 |
DCM-# pts (%) | 24 (24%) | 4 (16.7%) | =0.4 |
ASCVD risk score (%) | 12.16 ± 9.52 | 10.28 ± 11.98 | =0.6 |
LVEF (%) | 55 ± 13 | 59 ± 13 | =0.2 |
Statins-# pts (%) | 70 (70%) | 14 (58%) | =0.3 |
Betablockers-# pts (%) | 21(30%) | 4 (23%) | =0.6 |
Antithrombotics-# pts (%) | 51 (52%) | 11 (45%) | =0.5 |
ACEi-# pts (%) | 75 (75%) | 17 (71%) | =0.7 |
Diuretics-# pts (%) | 14 (14%) | 1 (4%) | =0.2 |
HDL = high-density lipoprotein; LDL = low-density lipoprotein; BMI= Body Mass Index; NYHA = New York Heart Association; DCM = dilated cardiomyopathy; ASCVD = atherosclerotic cardiovascular disease; LVEF = left ventricular ejection fraction; ACEi = Angiotensin converting enzyme inhibitor; pts= patients; in bold the p value that was significant.